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http:WHAT THIS PAPER ADDS
The results in this paper indicate that active smoking inﬂuences vascular cells to increase MMP-2 expression,
which contributes to expansion and the rupture risk of AAA. This ﬁnding prompts more aggressive control of
cardiovascular risk factors in the very early phase of the disease, and particularly AAA screening in smokers. This
could even modify monitoring guidelines for AAA in the non-surgical range, and the approach should be more
aggressive in patients who continue to smoke. It allows for the possibility that active smokers have a higher risk
of rupture than those with the same arterial diameter who do not smoke or who have stopped smoking.Objective: To evaluate the inﬂuence of cardiovascular risk factors on levels of matrix metalloproteinases (MMP)
2 and 9 in human abdominal aortic aneurysms (AAA).
Methods: Aortic samples were collected from patients who underwent AAA repair (n ¼ 89). Patients were
stratiﬁed according to the maximum transverse aorta diameter: small diameter (<55 mm), moderate diameter
(55e69.9 mm) and large diameter (70 mm). Aortic walls were studied using real-time PCR and
immunohistochemistry. MMP-2, MMP-9, a-actin, CD45, and CD68 transcript levels were determined relative to
b-actin. Quantitative data were expressed as median (IQ-range).
Results: No differences were found in MMP-2 expression between the patient groups, which was mainly
associated with vascular smooth muscle cells (VSMC); however, MMP-9 displayed the maximum level in the
moderate-diameter group, associated with inﬁltrating macrophages. Current smoking (CS) and renal insufﬁciency
(RI) signiﬁcantly increased local levels of MMP-2 (CS 349.5 [219.5e414.1] vs. no-CS 184.4 [100.0e320.5];
p < .008; RI 286.8 [189.6e410.8] vs. no-RI 177.3 [99.3e326.9]; p ¼ .047). Nevertheless, after stepwise linear
regression analysis only CS remained as an independent variable predicting local levels of MMP-2 (p ¼ .002). No
risk factors inﬂuenced local levels of MMP-9.
Conclusions: The results show that local levels of MMP-2, an important factor for AAA development, were
increased in current smoking AAA patients. MMP-2 was mainly associated with VSMC. It is suggested that MMP-2
could contribute signiﬁcantly to the increased AAA growth rate observed in current smoking patients. These
ﬁndings support inclusion of smokers in screening for aneurysmal disease, and emphasize the need for more
aggressive monitoring of aneurysmal disease outside the surgical range in patients who smoke at the time of
diagnosis and in those who continue to smoke during follow-up.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysm (AAA) is a common, late age
onset disorder in industrialized countries. Rupture of AAA
has very high mortality rates. Screening studies have sug-
gested that the prevalence of AAA in older men is about
5%.1 Despite the aging of the population, the prevalence,responding author. M. Camacho, Angiology, Vascular Biology and
ation Laboratory of the Institute of Research of Hospital Santa Creu
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//dx.doi.org/10.1016/j.ejvs.2014.05.023incidence, and global mortality rate of AAA appear to have
declined as a result of increased elective AAA repair, lower
mortality from emergency repair, and a greater proportion
of emergency admissions being offered emergency repair.2,3
The etiology of AAA is complex, but environmental and
genetic factors are known to contribute to the risk.4,5 The
relationship between AAA and atherosclerosis is intriguing.
Both disorders share some common features and AAA
usually occurs in atherosclerotic individuals. Not only are
there evident histopathological differences between AAA
and atherosclerotic lesions, but differences have also been
observed in cardiovascular risk factors. Diabetes, for
example, is a well-established risk factor for atherosclerosis,
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whereas smoking seems to be a substantially greater risk
factor for AAA than for atherosclerosis,7,8 and chronic
occlusive pulmonary disease (COPD) has been associated
with AAA.9
Current evidence on the pathogenesis of AAA indicates
that aortic wall inﬂammation and proteolytic degradation of
the aortic wall play a fundamental role in the evolution and
progression of the disease. A number of reports have
documented increased expression of matrix metal-
loproteinases (MMP) in AAA, and genetic variants have
been proposed to be associated with AAA.10 The MMPs
most prominently associated with AAA are MMP-2 (Gelat-
inase A) and MMP-9 (Gelatinase B),11e14 both of which
display elastolytic activity and similar proteolytic activity.15
One fundamental characteristic of AAA is the hyper-
vascularization of aortic tissue. It has been proposed that
this vascularization might contribute to the development of
aneurysms16 and could play a causative role in the genesis
of AAA.11,17 As several studies have pointed to the essential
role of MMP-2 and MMP-9 in the onset of angiogen-
esis,18,19 local levels of MMP-2 and MMP-9 could be rele-
vant in AAA progression.
Information is lacking on the inﬂuence of cardiovascular
risk factors on local levels of MMPs in AAA. The aim of the
present study was to evaluate the inﬂuence of the major
cardiovascular risk factors on MMP-2 and MMP-9 levels in
human AAA.
METHODS
Patients
The inclusion criteria for this study were patients under-
going elective open repair for atherosclerotic AAA. An
infrarenal aorta biopsy was taken during the intervention.
The exclusion criteria were absent or inadequate aortic bi-
opsy and patients with pseudoaneurysms, or infectious or
inﬂammatory aneurysms. Patients were stratiﬁed according
to the maximum transverse aorta diameter determined by
the use of a measurement transverse to the true lumen
center line at infrarenal level, based on angio-CT with
endovenous contrast, using Workstation AGFA IMPAX
6.4.0.4010 and OsiriX MD, FDA Cleared/CE IIa version, as a
primary diagnostic. Three groups were deﬁned: small
diameter (SD, <55 mm), moderate diameter (MD, 55e
69.9 mm) and large diameter (LD, 70 mm). Surgical repair
is not usually indicated when the maximum transverse
aortic diameter is <55 mm. The SD samples in this study
were obtained from patients with maximum transverse
aorta diameter <55 mm, who underwent surgery for a
symptomatic or rapidly growing AAA (>5 mm/6 month or
>10 mm/year) or for repair of a concomitant iliac artery
aneurysm.
All patients underwent surgery at Hospital de la Santa
Creu i Sant Pau (HSCSP). The study was approved by the
local ethics committee, and patients gave written informed
consent prior to surgery. All procedures were reviewed by
the institutional review board at HSCSP. The studyconformed to the principles of the Declaration of Helsinki.
Clinical outcomes were taken from the clinical database.
Tissue samples
Biopsies were systematically obtained from the antero-
lateral wall of the remaining mid-infrarenal aortic wall after
exclusion and prosthetic replacement of the AAA, at the
level of the inferior mesenteric artery. Luminal thrombi, if
present, were separated before the aortic biopsy was taken.
Biopsies were processed immediately. A portion of each
sample was placed in RNAlater solution (Qiagen GmbH,
Hilden, Germany) and stored at 4 C for 24 hours before
long-term storage at 80 C until further processing for
RNA isolation. When possible, another portion was ﬁxed in
10% formalin solution (Sigma-Aldrich, Inc St Louis, MO,USA)
for 24 hours and embedded in parafﬁn for microscopic
studies to locate the MMPs.
Endothelial cells and VSMC culture
Aortic human VSMC cultures were established from multi-
organ donor aortas using an explant procedure as previ-
ously described.20,21 VSMC were characterized by a-actin
positive staining and used at passage 4-6. Endothelial cells
were isolated by collagenase digestion from human umbil-
ical cord veins (HUVEC) and cultured as previously
described.22 Cells were characterized by vWF positive
staining and used at the ﬁrst passage.
Risk factors
The risk factor deﬁnitions used in this study were: diabetes
mellitus: glycated hemoglobin >5.8% or use of oral antidi-
abetic drugs or insulin; arterial hypertension (HTN): systolic
blood pressure 140 mm Hg, diastolic blood pressure
80 mm Hg or use of antihypertensive medication;
hyperlipidemia: a total cholesterol >6.2 mmol/L, LDL
cholesterol >1.70 mmol/L or triglycerides >1.65 mmol/L;
smoking was categorized into two groups: current smoking
(CS): smokers and ex-smokers stopped smoking <1 year,
and non-current smoking (N-CS): never-smoked and ex-
smokers stopped smoking >1year; COPD: FEV1/FVC <0.7;
and renal insufﬁciency (RI): estimated glomerular ﬁltration
rate (eGFR) was calculated with the Chronic Kidney Disease
Epidemiology Collaboration equation considering values of
eGFR 60 mL/min/1.73 m2 as RI.23
Analysis of mRNA levels in tissues and culture cells
Tissues were homogenized in the FastPrep-24 homogenizer
and Lysing Matrix D tubes (MP Biomedicals, Solon, OH,
USA). RNA was extracted using Trizol (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions. For
culture cells, total RNA was extracted using Ultraspec
(Biotecx Laboratories, Inc., Houston, TX, USA) according to
the manufacturer’s instructions. cDNA was prepared by
reverse transcribing 1 mg RNA with a High-Capacity cDNA
Archive Kit with random hexamers (Applied Biosystems,
Foster City, CA, USA). mRNA expression of the selected
Table 1. Demographics for AAA included in the study.
Total number patients 89
Aortic diameter (mm)a 66  12.7
SD (<55 mm) 49.9  6.5
MD (55e69.9 mm) 59.9  3.3
LD (70 mm) 80.2  6.9
Age (years) 71.1  6.5
Male 87 (97.8)
Diabetes mellitus 19 (21.3)
Hypertension 63 (70.8)
Hyperlipidemia 54 (60.7)
Smoking habit
Non-current smokersb 63 (70.8)
Current smokers 26 (29.2)
Coronary artery disease 20 (22.4)
Angina pectoris 2 (2.2)
Myocardial infarction 6 (6.7)
Coronary intervention/CABG 12 (13.5)
Chronic renal insufﬁciency 34 (38.2)
Dialysis 0
Peripheral vascular disease 48 (53.9)
Absent pulses 31 (34.8)
Intermittent claudication 17 (19.1)
Cerebrovascular disease 7 (7.9)
Cerebral vascular attack 4 (4.5)
Transient ischemic attack 3 (3.4)
COPD 26 (29.2)
Antiplatelet users 47 (53.4)
Statin users 57 (64)
ACE inhibitor users 23 (20.7)
NSAID users 6 (6.7)
Corticoid users 6 (6.7)
Immuno-suppressors 4 (3.5)
Nominal variables are presented as number and as percentage (%)
and continuous variables as mean  SD. ACE ¼ angiotensin
converting enzyme; CABG ¼ coronary artery bypass grafting;
COPD ¼ chronic obstructive pulmonary disease; LD ¼ large
diameter; MD ¼ moderate diameter; NSAID ¼ non-steroidal
anti-inﬂammatory drugs; SD ¼ small diameter.
a Aneurysm maximum transverse diameter in mm.
b Quit smoking >1 year.
376 J.-F. Dilmé et al.genes was studied by real-time PCR in an ABI Prism 7900HT
using pre-designed validated assays (TaqMan Gene
Expression Assays; Applied Biosystems) and universal ther-
mal cycling parameters. Relative expression was expressed
as transcript/b-actin ratios.
Immunohistochemistry
Immunohistochemistry was performed using a mouse
monoclonal antibody against MMP-2 (ref ab1818, diluted
1:15) from Abcam and a rabbit polyclonal antibody anti-
MMP-9 (ref A0150, diluted 1:50) from Dako. Three-
micrometer sections of parafﬁn-embedded tissue samples
were stained in a Dako Autostainer Link 48 using the Dako
EnVision Flex Kit. Diaminobenzidine was used as
chromogen.
Double-ﬂuorescence immunostaining
For antigen co-localization studies, double-ﬂuorescence
immunostaining was performed using a sequential
method. After deparafﬁnization and antigen retrieval,
blocking for non-speciﬁc binding was performed at 4 C
overnight. Appropriate concentrations of antibodies were
then sequentially applied for 1 hour at room temperature,
with PBS washing after each incubation. Slides were ﬁrst
incubated with anti-MMP-2 or anti-MMP-9 antibodies fol-
lowed by incubation with Alexa Fluor 488 goat-antimouse
IgG (diluted 1/200; Life Technologies, Carlsbad, CA, USA).
Next, MMP-2 slides were incubated with anti-alpha smooth
muscle Actin antibody (ref ab5694, diluted 1:200, Abcam),
and MMP-9 slides with CD45 or CD68 (IR751 and IR7613,
without further dilution, Dako), followed by incubation with
Alexa Fluor 555 donkey-antirabbit IgG (diluted 1/200; Life
Technologies). As a negative control, sections were incu-
bated omitting primary antibodies. Samples were then
mounted with ProLong Gold antifade reagent with DAPI
(Molecular Probes, Life Technologies Co, Eugene, OR, USA).
Images were obtained using an SP5 Leica confocal
microscope.
Statistical analysis
An exploratory study was performed to detect the rela-
tionship between cardiovascular risk factors and levels of
MMP-2 and MMP-9. SPSS and Sigma-Plot software were
used for statistical analysis. All data regarding transcript
levels are expressed relative to b-actin 1000. All quanti-
tative data in this study were non-normally distributed and
expressed as median (25the75th percentile). The Manne
Whitney Rank Sum Test was used to compare two groups
and KruskaleWallis one-way analysis of variance on ranks
for multiple comparisons. Bonferroni’s correction was
applied to adjust signiﬁcance values in multiple testing.
Pearson Product Moment Correlation after logarithmic
transformation of data was used to evaluate the association
between continuous variables with non-normal distribution.
A logarithmic transformation was applied to outcomes
without a normal distribution before data analysis using
linear regression tests, with an interaction analysis,including the effect of the identiﬁed risk factors and con-
trolling for possible confounding factors. A p value <0.05
was considered signiﬁcant.
RESULTS
From 2008 to 2012, elective abdominal aortic aneurysm
surgery was performed in 225 patients at the Department
of Vascular and Endovascular Surgery of the HSCSP in Bar-
celona, Spain. A total of 166 patients underwent open
surgery and 59 had endovascular aortic repair (EVAR). The
study group was made up of 89 of the 166 patients who
underwent open surgery. Table 1 shows patient
demographics.
Expression of MMP-2 and MMP-9
To evaluate levels of MMPs at different stages of AAA
development, AAA patient samples were stratiﬁed as a
function of the maximum transverse aorta diameter (see
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either MMP-2 or MMP-9 did not ﬁt a normal distribution.
Regarding expression of MMP-2, no signiﬁcant differences
were observed between stratiﬁed groups of patients,
whereas MMP-9 mRNA levels were statistically higher in the
MD group (Fig. 1).Localization of MMP-2 and MMP-9
Immunohistochemistry showed that MMP-2 was widely
expressed in AAA samples, with MMP-2 immunostaining
mainly found in medial VSMC (Fig. 2A) Additionally, MMP-2
was occasionally found in inﬁltrating leukocytes. Next, the
correlation was determined between mRNA levels of MMP-
2 and those of VSMC and leukocyte markers. The correlation
between MMP-2 and a-actin (VSMC marker) was very sig-
niﬁcant, that between MMP-2 and CD68 (a macrophage
marker) was much less signiﬁcant, and that between MMP-
2 and CD45 (pan-leukocyte marker) was not signiﬁcant
(Table 2). The mRNA levels of MMP-2 in HUVEC and VSMC
in culture were also examined, and MMP-2 was detected in
both vascular cell types (not shown). In immunoﬂuorescent
double staining, co-expression of MMP-2 and a-actin was
observed in some microvessels (Fig. 2B). Nevertheless, the
co-expression of these proteins was found mainly in VSMC
of the media layer (Fig. 2C).
Immunostaining with anti-MMP-9 was found in inﬁl-
trating leukocytes in AAA (Fig. 3A). No statistical association
was found between MMP-9 and a-actin, but a signiﬁcant
correlation was found between MMP-9 and leukocyte
markers, with the highest correlation being between MMP-
9 and CD68 (Table 2). MMP-9 was not detected in either
HUVEC or VSMC in culture (not shown). Immunoﬂuores-
cence showed that MMP-9 co-expressed with CD45 in some
cells (Fig. 3B), but mainly with CD68 (Fig. 3C).Inﬂuence of risk factors on MMP-2 and MMP-9 transcript
levels
When AAA patients were stratiﬁed according to risk factors
it was found that MMP-2 transcript levels were statistically
higher in CS than in N-CS (Table 3). As described in theSD MD LD
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Figure 1. Expression levels of MMP-2 and MMP-9 in stratiﬁed
patient groups as a function of the maximum aorta diameter; SD:
<55 mm, n ¼ 14; MD: 55e69.9 mm, n ¼ 42; and LD: 70 mm,
n ¼ 33.
Figure 2. (A) Representative immunohistochemistry images of
MMP-2 in AAA samples. Arrows show medial VSMC immuno-
stained with anti-MMP-2. (B) Representative immunoﬂuorescent
double staining for MMP-2 and a-actin of a leukocyte inﬁltration
area in the media. Arrows show double immunostained cells; M
indicates the light of microvessels; bars are 25 mm. (C) Repre-
sentative immunoﬂuorescent double staining for MMP-2 and a-
actin of non-inﬁltrated area in the media layer. Arrows show some
double immunostained cells; bars are 15 mm.Methods, the N-CS group consisted of both never-smoked
and ex-smokers. In previous statistical analysis, the CS
group was different from ex- and never-smoked groups
regarding MMP-2. As there were no differences between
these two groups regarding MMP-2 in this study, they were
joined to increase statistical power as there were only seven
never-smokers. Patients with RI also exhibited a higher
Table 2. Correlation values between mRNA levels of MMP-2 and
MMP-9 and those of VSMC or leukocyte markers.
n MMP-2 MMP-9
R pa R pa
a-actin 86 .512 1.7  106 .148 .665
CD45 86 .191 .365 .319 .012
CD68 66 .382 .012 .609 3.56  107
a Pearson Product Moment Correlation after logarithmic trans-
formation of data and Bonferroni’s correction for multiple testing
was applied.
378 J.-F. Dilmé et al.MMP-2 expression than patients with normal eGFR. No
differences in MMP-2 levels were found between the
groups regarding the other risk factors. The association
between risk factors was then evaluated. After c2 analysis,
CS, HTN, COPD, and RI were identiﬁed as possibly related
variables (Table 4). A logarithmic transformation was
applied to the outcomes of MMP2 and eGFR, which did not
ﬁt a normal distribution prior to the multiple linear
regression analysis. Despite the statistical signiﬁcance in the
univariate analysis, the multiple linear regression analysis
ruled out a relationship between MMP2 and RI and no
interaction was detected (Table 4). After stepwise linear
regression analysis, only CS (p ¼ .002) remained an inde-
pendent variable predicting MMP-2 levels; and the ﬁnal
model was: LogMMP-2 ¼ 2.242 þ 0.259$CS; R ¼ .329.
Calculating the antilogarithms, the predicted level of MMP-
2 of the N-CS was 174.54 and of the CS was 316.66. No
differences were found in the expression of MMP-9 be-
tween the AAA risk factor groups (Table 3).Figure 3. (A) Representative immunohistochemistry images of
MMP-9 in AAA. Arrows show medial inﬁltrating leukocytes
immunostained with anti-MMP-9. (B) Representative immunoﬂu-
orescent double staining for MMP-9 and CD45 of a leukocyte
inﬁltration area in the media. Arrows show some double immu-
nostained cells; bars are 25 mm. (C) Representative immunoﬂuo-
rescent double staining for MMP-9 and CD68 of a leukocyte
inﬁltration area in the media. Arrows show some double immu-
nostained cells; bars are 25 mm.DISCUSSION
This study describes the inﬂuence of cardiovascular risk
factors on local levels of MMP-2 and MMP-9 in human
aneurysmal aorta. The main characteristics that distinguish
AAA from atherosclerosis are proteolytic degradation of
elastic ﬁbers, VSMC depletion, and hypervascularization of
aortic tissue. In these processes, MMPs, in particular MMP-
2 and MMP-9, play a fundamental role.11,16e19
Previous reports show increased MMP-2 and MMP-9
levels in AAA.11e14 In this study, when patients were
stratiﬁed according to maximum AAA diameter, levels of the
two MMPs transcripts displayed different patterns: whereas
MMP-2 levels were similar in all diameter-stratiﬁed groups,
MMP-9 showed maximum expression in the MD group.
Previous reports have shown maximal expression of MMP-2
in small AAA and MMP-9 in medium size AAA.13,14 These
results are also consistent with a previous report showing
that expression of CD45, MMP-9, and ﬁve lipoxygenase
activating protein, another leukocyte associated protein,
was signiﬁcantly enhanced in AAA patients, with maximal
expression in the MD group.17 In the present study,
immunohistochemistry showed that MMP-2 and MMP-9
also differed in cellular localization. Whereas MMP-2 was
expressed mainly in medial VSMC, MMP-9 was detected
only in the inﬁltrating leukocytes. Transcript ﬁndings sup-
ported these data. A good correlation was found betweenMMP-2 and a-actin transcript levels, whereas correlation of
MMP-2 with leukocyte markers was weak. In contrast,
MMP-9 showed a correlation with transcript levels of the
leukocyte markers CD45 and CD68, with the best correlation
being between MMP-9 and CD68. Taken together, these
results indicate that MMP-2 was mainly associated with
VSMC and, as reported by Newman et al.,24 MMP-9 was
associated with inﬁltrating leukocytes, mainly macrophages.
Table 3. Transcript levels of MMP-2 and MMP-9 in AAA samples
stratiﬁed by cardiovascular risk factors.
Median 25the75th
percentile
p vs.
no-factora
MMP-2
No current smoking 184.4 100.0e320.5
Current smoking 349.5 219.5e414.1 .008
No renal insufﬁciency 177.3 99.3e326.9
Renal insufﬁciency 286.8 189.6e410.8 .047
No hypertension 232.7 170.2e335.8
Hypertension 216.2 109.5e394.8 >.999
No diabetes mellitus 217.0 132.6e351.4
Diabetes mellitus 224.3 86.5e394.1 >.999
No hyperlidemia 219.5 104.7e347.3
Hyperlipedemia 221.0 132.6e363.4 >.999
No COPD 207.0 109.5e334.9
COPD 232.4 170.0e404.3 .743
MMP-9
No current smoking 67.2 38.8e122.5
Current smoking 61.7 35.4e110.1 >.999
No renal insufﬁciency 64.9 38.1e119.1
Renal insufﬁciency 75.8 29.1e120.2 >.999
No hypertension 65.6 37.8e110.1
Hypertension 66.0 34.3e123.0 >.999
No diabetes mellitus 67.7 38.1e119.1
Diabetes mellitus 60.9 31.3e120.2 >.999
No hyperlidemia 72.8 41.6e143.3
Hyperlipedemia 62.2 26.6e115.0 .957
No COPD 64.1 39.0e135.6
COPD 67.1 26.6e105.3 >.999
Data are expressed as relative to b-actin 1000. COPD ¼ chronic
obstructive pulmonary disease.
a ManneWhitney Rank Sum test and Bonferroni’s correction for
multiple testing was applied.
Table 4. Association between risk factors and multiple linear regressio
c2 analysis of risk factors
Variable COPD CS
HTN c2 ¼ 1.494
p ¼ .222
c2 ¼ 3.371
p ¼ .066
COPD c2 ¼ 8.464
p ¼ .004
CS
DM
HL
Multiple linear regression
Log10(MMP-2) ¼ a0 þ a1$CS þ a2$Log10(eGFR) þ a3$COPD þ a4$HT
Variable Coefﬁcient Coefﬁcient value
a0 2.885
CS a1 0.206
eGFR a2 0.339
COPD a3 0.044
HTN a4 0.049
COPD ¼ chronic obstructive pulmonary disease; CS ¼ current smokin
hypertension; RI ¼ renal insufﬁciency.
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9 may not be regulated by the same mechanisms and may
therefore have different roles in AAA development.11e14 It
has been postulated that MMP-2 plays a role in the
expansion of AAA and MMP-9 in the progression towards
rupture.12
Although AAA and atherosclerosis are related inﬂamma-
tory diseases, not all cardiovascular risk factors for athero-
sclerosis are associated with AAA. Differences were found
regarding the inﬂuence of cardiovascular risk factors on
local levels of MMP-2 and MMP-9 in AAA. None of the
evaluated risk factors inﬂuenced local levels of MMP-9. In
contrast, univariate analysis indicated that CS and RI pa-
tients had higher MMP-2 levels in the aneurysmal aorta
than N-CS and non-RI individuals. Many reports provide
evidence supporting an association between renal function
and atherosclerosis, and eGFR is an independent prognostic
factor for cardiovascular disease.25 It was recently reported
that eGFR is an excellent predictor of vascular events in
patients with peripheral arterial disease.26 Taking solely the
univariate statistical analysis of RI data and MMP-2
expression into account, it could be concluded that the
degree of atherosclerosis inﬂuenced MMP-2 levels. Never-
theless, multiple linear regression analysis indicated that
the inﬂuence of RI, in terms of eGFR, on MMP-2 local levels
was weak, if present at all. Taken together, these results
suggest that the effect of smoking on local levels of MMP-2
is independent of the atherosclerotic and COPD states in
AAA patients. Indeed, it has previously been reported that
the association of COPD and AAA is unrelated to smoking.9
Smoking is a particularly relevant risk factor for AAA.27 It
has been reported that the association between smoking
and AAA is 2.5-fold higher than the association between
smoking and coronary heart disease.8 Tobacco smoke alson analysis; MMP-2 as independent variable.
DM HL RI
c2 ¼ 1.801
p ¼ .180
c2 ¼ 0.032
p ¼ .859
c2 ¼ 4.448
p ¼ .035
c2 ¼ 0.001
p ¼ .981
c2 ¼ 0.082
p ¼ .775
c2 ¼ 9.952
p ¼ .002
c2 ¼ 0.033
p ¼ .857
c2 ¼ 0.001
p ¼ .976
c2 ¼ 1.223
p ¼ .269
c2 ¼ 2.55
p ¼ .110
c2 ¼ 0.040
p ¼ .842
c2 ¼ 0.003
p ¼ .957
N; R ¼ 0.378381
Coefﬁcient Std. Error p
0.434 <.001
0.087 .019
0.220 .126
0.088 .615
0.088 .576
g; DM ¼ diabetes mellitus; HL ¼ hyperlipidemia; HTN ¼ arterial
380 J.-F. Dilmé et al.enhances AAA formation in animal models.28,29 A statisti-
cally signiﬁcant difference was found between CS and N-CS
regarding MMP-2, and this was maintained after intro-
ducing RI, HTN, and COPD as confounding variables into the
statistics. From the present data, it seems that MMP-2 is
mainly linked to the VSMC state, whereas local levels of
MMP-9 appear to depend more on the inﬂammatory inﬁl-
trate in the aortic wall. This suggests that smoking affects
the state of VSMC rather than the degree of leukocyte
inﬁltration. As MMP-2 plays a role in the expansion of
AAA,12 the present results suggest that it could signiﬁcantly
contribute to the increased AAA growth rate observed in
the smoking patients.7
Several studies on the biochemical effects of tobacco
smoke are available. Water-soluble tobacco smoke extract
has been found to induce MMP-1 expression in endothelial
cells and neutrophil elastase in AAA.30,31 It has also been
observed that nicotine induces AAA in an animal model
through activation of AMP activated protein kinase
alpha2.32 Nevertheless, more research is needed to ascer-
tain the molecular species and signaling pathways involved
in the effect of tobacco smoke on MMP-2 expression in
human AAA, particularly in VSMC.
In conclusion, the present work shows that current
smoking patients had higher MMP-2 levels than non-
current smokers. However, no correlation was found be-
tween MMP-9 and smoking. These results add further evi-
dence for the role of tobacco smoking in AAA development,
supporting the need to include smokers in AAA screening,
and to implement more aggressive monitoring of aneu-
rysmal disease outside the surgical range (<5.5 cm) in pa-
tients who smoke at the time of diagnosis and in those who
continue to smoke during follow-up. More research is
needed to elucidate the pathways involved in the regulation
of MMP-2 expression by tobacco smoke in AAA, particularly
in VSMC.FUNDING
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